真菌CYP51抑制剂VT-1161和VT-1129对临床分离的对唑类和棘白菌素类抗真菌化合物耐药的光滑念珠菌和克柔念珠菌菌株表现出强大活性。
Fungal CYP51 Inhibitors VT-1161 and VT-1129 Exhibit Strong Activity against Candida glabrata and C. krusei Isolates Clinically Resistant to Azole and Echinocandin Antifungal Compounds.
作者信息
Schell W A, Jones A M, Garvey E P, Hoekstra W J, Schotzinger R J, Alexander B D
机构信息
Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
Viamet Pharmaceuticals, Inc., Durham, North Carolina, USA.
出版信息
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.01817-16. Print 2017 Mar.
Abstract
The activities of fungal CYP51 inhibitors VT-1161 and VT-1129 were determined for ( = 34) and ( = 50). isolates were screened for FKS gene mutations. All isolates were resistant clinically and/or to at least one standard antifungal compound. VT-1161 and VT-1129 MICs for all isolates were at least 5-fold below achievable human plasma levels for VT-1161. VT-1161 and VT-1129 are promising for the treatment of resistant and infections.
摘要
测定了真菌CYP51抑制剂VT - 1161和VT - 1129对34株烟曲霉和50株白色念珠菌的活性。对分离株进行FKS基因突变筛查。所有分离株在临床和/或对至少一种标准抗真菌化合物耐药。所有分离株的VT - 1161和VT - 1129最低抑菌浓度（MIC）比VT - 1161在人体血浆中可达到的水平低至少5倍。VT - 1161和VT - 1129在治疗耐药烟曲霉和白色念珠菌感染方面很有前景。
相似文献
1
Fungal CYP51 Inhibitors VT-1161 and VT-1129 Exhibit Strong Activity against Candida glabrata and C. krusei Isolates Clinically Resistant to Azole and Echinocandin Antifungal Compounds.
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.01817-16. Print 2017 Mar.
2
Activities of the Novel Investigational Tetrazoles VT-1161 and VT-1598 Compared to the Triazole Antifungals against Azole-Resistant Strains and Clinical Isolates of .
Antimicrob Agents Chemother. 2019 May 24;63(6). doi: 10.1128/AAC.00341-19. Print 2019 Jun.
3
Absence of Azole or Echinocandin Resistance in Candida glabrata Isolates in India despite Background Prevalence of Strains with Defects in the DNA Mismatch Repair Pathway.
Antimicrob Agents Chemother. 2018 May 25;62(6). doi: 10.1128/AAC.00195-18. Print 2018 Jun.
4
Azole Resistance Reduces Susceptibility to the Tetrazole Antifungal VT-1161.
Antimicrob Agents Chemother. 2018 Dec 21;63(1). doi: 10.1128/AAC.02114-18. Print 2019 Jan.
5
Rate of FKS Mutations among Consecutive Candida Isolates Causing Bloodstream Infection.
Antimicrob Agents Chemother. 2015 Dec;59(12):7465-70. doi: 10.1128/AAC.01973-15. Epub 2015 Sep 21.
6
Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.
Antimicrob Agents Chemother. 2015 Oct 19;60(1):229-38. doi: 10.1128/AAC.02157-15. Print 2016 Jan.
7
Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.
Clin Infect Dis. 2013 Jun;56(12):1724-32. doi: 10.1093/cid/cit136. Epub 2013 Mar 13.
8
Spontaneous Mutational Frequency and Mutation Rates Vary by Echinocandin Agent against .
Antimicrob Agents Chemother. 2018 Dec 21;63(1). doi: 10.1128/AAC.01692-18. Print 2019 Jan.
9
In Vitro Exposure to Increasing Micafungin Concentrations Easily Promotes Echinocandin Resistance in Candida glabrata Isolates.
Antimicrob Agents Chemother. 2017 Jan 24;61(2). doi: 10.1128/AAC.01542-16. Print 2017 Feb.
10
Echinocandin resistance and population structure of invasive Candida glabrata isolates from two university hospitals in Germany and Austria.
Mycoses. 2016 May;59(5):312-8. doi: 10.1111/myc.12472. Epub 2016 Jan 25.
引用本文的文献
1
Draft genome sequence and annotation of the enfumafungin producing fungus Hormonema carpetanum ATCC 74360.
BMC Genom Data. 2025 Aug 8;26(1):55. doi: 10.1186/s12863-025-01348-9.
2
Beyond Conventional Antifungals: Combating Resistance Through Novel Therapeutic Pathways.
Pharmaceuticals (Basel). 2025 Mar 4;18(3):364. doi: 10.3390/ph18030364.
3
Antifungal Susceptibility Testing - The Times They Are a Changin'.
Clin Microbiol Newsl. 2019 May 15;41(10):85-90. doi: 10.1016/j.clinmicnews.2019.04.006.
4
The evolution of antifungal therapy: Traditional agents, current challenges and future perspectives.
Curr Res Microb Sci. 2025 Jan 11;8:100341. doi: 10.1016/j.crmicr.2025.100341. eCollection 2025.
5
Azole Combinations and Multi-Targeting Drugs That Synergistically Inhibit .
J Fungi (Basel). 2024 Oct 7;10(10):698. doi: 10.3390/jof10100698.
6
Pichia kudriavzevii (Candida krusei): A systematic review to inform the World Health Organisation priority list of fungal pathogens.
Med Mycol. 2024 Jun 27;62(6). doi: 10.1093/mmy/myad132.
7
Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease.
Clin Microbiol Rev. 2024 Jun 13;37(2):e0007423. doi: 10.1128/cmr.00074-23. Epub 2024 Apr 11.
8
Oteseconazole versus fluconazole for the treatment of severe vulvovaginal candidiasis: a multicenter, randomized, double-blinded, phase 3 trial.
Antimicrob Agents Chemother. 2024 Jan 10;68(1):e0077823. doi: 10.1128/aac.00778-23. Epub 2023 Dec 14.
9
The Role of Novel Antifungals in the Management of Candidiasis: A Clinical Perspective.
Mycopathologia. 2023 Dec;188(6):937-948. doi: 10.1007/s11046-023-00759-5. Epub 2023 Jul 20.
10
Novel Therapeutic Approaches to Invasive Candidiasis: Considerations for the Clinician.
Infect Drug Resist. 2023 Feb 22;16:1087-1097. doi: 10.2147/IDR.S375625. eCollection 2023.
本文引用的文献
1
Prevalent mutator genotype identified in fungal pathogen Candida glabrata promotes multi-drug resistance.
Nat Commun. 2016 Mar 29;7:11128. doi: 10.1038/ncomms11128.
2
The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattii.
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2528-31. doi: 10.1128/AAC.02770-15. Print 2016 Apr.
3
Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis.
Antimicrob Agents Chemother. 2015 Sep;59(9):5567-73. doi: 10.1128/AAC.00185-15. Epub 2015 Jun 29.
4
VT-1161 dosed once daily or once weekly exhibits potent efficacy in treatment of dermatophytosis in a guinea pig model.
Antimicrob Agents Chemother. 2015 Apr;59(4):1992-7. doi: 10.1128/AAC.04902-14. Epub 2015 Jan 20.
5
The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme.
Antimicrob Agents Chemother. 2014 Dec;58(12):7121-7. doi: 10.1128/AAC.03707-14. Epub 2014 Sep 15.
6
Design and optimization of highly-selective fungal CYP51 inhibitors.
Bioorg Med Chem Lett. 2014 Aug 1;24(15):3455-8. doi: 10.1016/j.bmcl.2014.05.068. Epub 2014 Jun 9.
7
Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata.
J Clin Microbiol. 2012 Apr;50(4):1199-203. doi: 10.1128/JCM.06112-11. Epub 2012 Jan 25.
8
Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009.
Antimicrob Agents Chemother. 2011 Feb;55(2):561-6. doi: 10.1128/AAC.01079-10. Epub 2010 Nov 29.
9
Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database.
Clin Infect Dis. 2010 Apr 15;50(8):1091-100. doi: 10.1086/651263.
10
Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET).
Clin Infect Dis. 2010 Apr 15;50(8):1101-11. doi: 10.1086/651262.
Zotero 插件